Researchers from England used pigs to test vaccines against the novel corona virus. To do this, they take advantage of the similarity of the immune and respiratory systems of pigs and humans.
Scientists from England now want to use pigs to fight the new SARS-CoV-2 coronavirus. In collaboration with researchers from Oxford University and Public Health England, a team of scientists from the Pirbright Institute will begin testing new vaccines for their ability to raise protective antibodies against SARS-CoV-2.
Among other things, the chimpanzee adenovirus vaccine vector that was used to produce vaccines against Ebola, the Middle East respiratory syndrome and the flu is tested.
The vaccine candidates developed will contain the spike protein of SARS-CoV-2. This is the protein against which protective antibodies are formed in infected people. To do this, the researchers measure the amount of antibodies produced after injecting vaccine candidates into pigs.
Pig and human respiratory system and immune system very similar (!!!)
They take advantage of the fact that pig and human immune systems have significant similarities. It can be assumed that a good response to a vaccine candidate in pigs is also promising in humans.
At the same time, the scientists will also test the safety of the new vaccines and check whether there are any adverse side effects in the pigs. If this attempt is successful, the next step could be to investigate the possible vaccine in humans.
The scientists from Pirbright are already using pigs for research on influenza viruses. Pigs have so far been used as large animal models because they have a very similar respiratory system to that of humans. In addition, they inherently become infected with influenza viruses and form antibodies with properties similar to those of humans.
Pigs are therefore a suitable model for carrying out research for the novel corona virus.
The vaccine vector used cannot cause infection
“The vector vaccine developed at Oxford is used in this SARS-CoV-2 vaccine research because it can produce a strong immune response at a low dose,” explains Bryan Charleston, director of the Pirbright Institute.
“The vaccine vector is not replicable, which means that it cannot cause infection in an individual. This makes its application safer for people with underlying health conditions such as diabetes.
This approach has been applied to other vaccines and we hope that this research will enable the vaccine to advance to the next phase of human testing. ”
And I mean…We are very lucky again!
With a success rate of 5% (which generally affects all results from animal experiments on humans), we will control the healing process of the corona as slowly as that of the Spanish flu.
100 years ago, it took a year; today if we test on pigs it will probably take even longer.
The human being is the only animal that does not learn from its mistakes.
My best regards to all, Venus